Literature DB >> 9765445

Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1.

M E Quiñones-Mateu1, J L Albright, A Mas, V Soriano, E J Arts.   

Abstract

Nucleotide sequences of the reverse transcriptase (RT) coding region have been compared in four new human immunodeficiency virus type 1 (HIV-1) group O isolates. Phylogenetic analysis of this pol region highlights a cluster of these four HIV-1 group O sequences with seven other group O isolates (5% intracluster nucleotide sequence diversity) similar to clusters classified as subtypes in HIV-1 group M (an average of 4.9% intrasubtype sequence diversity). Based on these analyses, this group O cluster has been designated subtype A-O. A longitudinal study of a heterosexual couple infected with group O (ESP1 and ESP2) allowed a detailed analysis of RT sequences (amino acids 28 to 219). Directed evolution and a slightly higher mutation frequency was observed in the RT sequences of patient ESP2, treated with antiretroviral drugs, than that from the untreated patient ESP1. Antiretroviral treatment also selected for specific substitutions, M184V and T215Y in the RT coding region, conferring resistance to 3'-dideoxy-3'-thiacytidine and zidovudine, respectively. A Gly98 to Glu RT substitution identified in the treated patient suggests a possible reversion of a nonnucleoside RT inhibitor-resistant phenotype. Using RT clones from this longitudinal study, both heteroduplex tracking assay and cloning-sequencing techniques were employed for an extensive genetic analysis of pol gene quasispecies. Amino acid substitutions (i.e., Phe-77 to Leu, Lys-101 to Glu, and Val-106 to Iso) associated with antiretroviral resistance were identified in RT clones from HIV-1 group O-infected patients not subjected to drug therapy or treated with unrelated drugs. Finally, phylogenetic relationships between RT clones of the treated ESP2 patient and those of the untreated ESP1 patient show how drug pressure can direct evolution of viral pol gene quasispecies independently of direct drug-resistant substitutions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9765445      PMCID: PMC110317     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Genotypic subtypes of HIV-1 in Cameroon.

Authors:  J N Nkengasong; W Janssens; L Heyndrickx; K Fransen; P M Ndumbe; J Motte; A Leonaers; M Ngolle; J Ayuk; P Piot
Journal:  AIDS       Date:  1994-10       Impact factor: 4.177

2.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.

Authors:  J M Coffin
Journal:  Science       Date:  1995-01-27       Impact factor: 47.728

Review 3.  Tenth anniversary perspectives on AIDS. HIV: between past and future.

Authors:  G Myers
Journal:  AIDS Res Hum Retroviruses       Date:  1994-11       Impact factor: 2.205

4.  Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections.

Authors:  C Schable; L Zekeng; C P Pau; D Hu; L Kaptue; L Gurtler; T Dondero; J M Tsague; G Schochetman; H Jaffe
Journal:  Lancet       Date:  1994-11-12       Impact factor: 79.321

5.  Isolation and envelope sequence of a highly divergent HIV-1 isolate: definition of a new HIV-1 group.

Authors:  P Charneau; A M Borman; C Quillent; D Guétard; S Chamaret; J Cohen; G Rémy; L Montagnier; F Clavel
Journal:  Virology       Date:  1994-11-15       Impact factor: 3.616

6.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.

Authors:  J D Thompson; D G Higgins; T J Gibson
Journal:  Nucleic Acids Res       Date:  1994-11-11       Impact factor: 16.971

7.  Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades.

Authors:  A Gervaix; X Li; G Kraus; F Wong-Staal
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

8.  HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients.

Authors:  I Loussert-Ajaka; T D Ly; M L Chaix; D Ingrand; S Saragosti; A M Couroucé; F Brun-Vézinet; F Simon
Journal:  Lancet       Date:  1994-06-04       Impact factor: 79.321

9.  Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy.

Authors:  I Nájera; A Holguín; M E Quiñones-Mateu; M A Muñoz-Fernández; R Nájera; C López-Galíndez; E Domingo
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

10.  Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

Authors:  T Shirasaka; M F Kavlick; T Ueno; W Y Gao; E Kojima; M L Alcaide; S Chokekijchai; B M Roy; E Arnold; R Yarchoan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

View more
  18 in total

1.  Quantitation of human immunodeficiency virus type 1 group O load in plasma by measuring reverse transcriptase activity.

Authors:  J G García Lerma; V Soriano; A Mas; M E Quiñones-Mateu; E J Arts; W Heneine
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

2.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

Review 3.  Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.

Authors:  L Buonaguro; M L Tornesello; F M Buonaguro
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

4.  Rapid assessment of phenotypic resistance to protease inhibitors in human immunodeficiency virus type 1 group O.

Authors:  Berta Rodés; Eva Poveda; Vincent Soriano
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

5.  The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates.

Authors:  Kevin K Ariën; Awet Abraha; Miguel E Quiñones-Mateu; Luc Kestens; Guido Vanham; Eric J Arts
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 group m protease in cameroon: genetic diversity and protease inhibitor mutational features.

Authors:  Peter N Fonjungo; Eitel N Mpoudi; Judith N Torimiro; George A Alemnji; Laura T Eno; Esther J Lyonga; John N Nkengasong; Renu B Lal; Mark Rayfield; Marcia L Kalish; Thomas M Folks; Danuta Pieniazek
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

7.  Diversity, divergence, and evolution of cell-free human immunodeficiency virus type 1 in vaginal secretions and blood of chronically infected women: associations with immune status.

Authors:  Sharon T Sullivan; Usha Mandava; Tammy Evans-Strickfaden; Jeffrey L Lennox; Tedd V Ellerbrock; Clyde E Hart
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

8.  Next-Generation Sequencing to Help Monitor Patients Infected with HIV: Ready for Clinical Use?

Authors:  Richard M Gibson; Christine L Schmotzer; Miguel E Quiñones-Mateu
Journal:  Curr Infect Dis Rep       Date:  2014-04       Impact factor: 3.725

9.  In vitro intersubtype recombinants of human immunodeficiency virus type 1: comparison to recent and circulating in vivo recombinant forms.

Authors:  Miguel E Quiñones-Mateu; Yong Gao; Sarah C Ball; Andre J Marozsan; Awet Abraha; Eric J Arts
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Turnover of env variable region 1 and 2 genotypes in subjects with late-stage human immunodeficiency virus type 1 infection.

Authors:  Kathryn M Kitrinos; Noah G Hoffman; Julie A E Nelson; Ronald Swanstrom
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.